TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Northern Technologies International Corporation
Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026

Northern Technologies International Corporation (NTIC) reported Q1 FY2026 results with consolidated net sales reaching a quarterly record of $23.3 million, up 9.2% year-over-year. While ZERUST® oil and gas sales surged 58.1% and NTIC China grew 23.5%, gross profit margin declined 230 basis points to 36.0% due to supplier lead-time issues. Net income fell to $238,000 from $561,000 despite record sales, primarily due to higher operating expenses and an unusually high effective tax rate of 34.4%. Management expects profitability to improve in subsequent quarters as sales growth outpaces operating expense growth.

Insights
USARW   positive

The company is strategically expanding its capabilities by acquiring a key metal manufacturer, which enhances its supply chain, provides access to critical relationships, and supports domestic rare earth production

NTIC   neutral

Mixed results with positive revenue growth (9.2% increase to record sales) and strong performance in key segments (oil & gas +58.1%, China +23.5%), but offset by declining profitability (net income down 58% YoY), compressed gross margins (down 230 bps), and elevated tax rates. Management's optimistic forward guidance and expectations for margin recovery provide some positive outlook, but current quarter performance shows profitability challenges despite top-line strength.

Keywords
#corrosion inhibiting products #ZERUST® #Natur-Tec® #gross margin decline #oil and gas segment #China operations #operating expenses #tax rate #working capital

Tickers
NTIC
← Prev: Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria